Aprea Therapeutics Files 8-K on Financials and Operations

TL;DR

APRE files 8-K: Updates on financials and operations. Check for details.

AI Summary

Aprea Therapeutics, Inc. filed an 8-K on October 9, 2024, reporting on its results of operations, other events, and financial statements. The filing details the company's financial condition and any significant occurrences during the reporting period.

Why It Matters

This filing provides investors with crucial updates on Aprea Therapeutics' financial health and operational activities, impacting investment decisions.

Risk Assessment

Risk Level: medium — 8-K filings can contain significant news that may impact stock price, requiring careful review by investors.

Key Players & Entities

• Aprea Therapeutics, Inc. (company) — Registrant
• October 9, 2024 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 3805 Old Easton Road (address) — Principal Executive Offices
• Doylestown, PA (location) — Principal Executive Offices City/State
• 18902 (zip_code) — Principal Executive Offices Zip Code
• ( 617 ) 463-9385 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar
• $26.2 million — nd cash equivalents to be approximately $26.2 million as of September 30, 2024, down sequenti
• $28.7 million — quentially as compared to approximately $28.7 million as of June 30, 2024. This estimate of

Filing Documents

• tm2425851d1_8k.htm (8-K) — 28KB
• tm2425851d1_ex99-1.htm (EX-99.1) — 16KB
• tm2425851d1_ex99-1img01.jpg (GRAPHIC) — 4KB
• 0001104659-24-107219.txt ( ) — 226KB
• apre-20241009.xsd (EX-101.SCH) — 3KB
• apre-20241009_lab.xml (EX-101.LAB) — 33KB
• apre-20241009_pre.xml (EX-101.PRE) — 22KB
• tm2425851d1_8k_htm.xml (XML) — 4KB

02

Item 2.02 Results of Operations and Financial Condition. Aprea Therapeutics, Inc. (the "Company") is currently finalizing its financial quarterly closing process for the three months ended September 30, 2024. While complete financial information and operating data are not yet available, the Company expects cash and cash equivalents to be approximately $26.2 million as of September 30, 2024, down sequentially as compared to approximately $28.7 million as of June 30, 2024. This estimate of cash and cash equivalents is preliminary and subject to completion. As a result, this unaudited preliminary financial information reflects the Company's preliminary estimate with respect to such information, based on information currently available to management, and may vary from the Company's actual financial position as of September 30, 2024. The unaudited preliminary cash and cash equivalents figure included in this Current Report on Form 8-K has been prepared by, and is the responsibility of, the Company's management. The Company's independent registered public accounting firm, EisnerAmper LLP, has not audited, reviewed, compiled or completed its procedures with respect to such unaudited financial information and, accordingly, EisnerAmper LLP does not express an opinion or any other form of assurance with respect thereto. It is possible that the Company or its independent registered public accounting firm may identify items that require the Company to make adjustments to the financial information set forth above.

01

Item 8.01 Other Events. On October 9, 2024, the Company issued a press release announcing that the Company engaged Phillipe Pultar, MD to serve as its Senior Medical Advisor and that Dr. Nadeem Mirza will be stepping down as Chief Medical Officer effective as of October 9, 2024, to pursue other professional endeavors but will remain with the Company through a date not later than December 13, 2024, to ensure a smooth leadership transition. The full text of the press release is filed herewith as Exhibit 99.1 and incorporated herein by reference.

01 -

Item 9.01 - Financial (d) Exhibits Exhibit Number Description 99.1 Press Release, dated October 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 9, 2024 APREA THERAPEUTICS, INC. By: /s/ Oren Gilad Oren Gilad, Ph.D., Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR